Design Therapeutics, Inc.

DSGN

$114M

Micro Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaCARLSBAD55 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 6, 2026

Market Overview

Stock performance and key metrics

DSGN News

Catalyst Timeline

3 upcoming, 0 past

No catalysts found.

3 more catalysts beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

Drug Pipeline

DT-216P2

Phase 2

Friedreich Ataxia

DT-168

Phase 2

Fuchs Endothelial Corneal Dystrophy

Drug Name	Phase	Indication	Designations	Patent
DT-216P2	Phase 2	Friedreich Ataxia	-	-
DT-168	Phase 2	Fuchs Endothelial Corneal Dystrophy	-	-

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Design Therapeutics, Inc.

Market Overview

DSGN News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals